Cargando…

Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent

PURPOSE: The high-intensity focused ultrasound (HIFU) ablation of tumors is inseparable from synergistic agents and image monitoring, but the existing synergistic agents have the defects of poor targeting and a single imaging mode, which limits the therapeutic effects of HIFU. The construction of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yaotai, Chen, Chun, Luo, Yong, Xiong, Jie, Tang, Yu, Yang, Haiyan, Wang, Lu, Jiang, Fujie, Gao, Xuan, Xu, Die, Li, Huanan, Wang, Qi, Zou, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085950/
https://www.ncbi.nlm.nih.gov/pubmed/32256065
http://dx.doi.org/10.2147/IJN.S238398
_version_ 1783509044802093056
author Wang, Yaotai
Chen, Chun
Luo, Yong
Xiong, Jie
Tang, Yu
Yang, Haiyan
Wang, Lu
Jiang, Fujie
Gao, Xuan
Xu, Die
Li, Huanan
Wang, Qi
Zou, Jianzhong
author_facet Wang, Yaotai
Chen, Chun
Luo, Yong
Xiong, Jie
Tang, Yu
Yang, Haiyan
Wang, Lu
Jiang, Fujie
Gao, Xuan
Xu, Die
Li, Huanan
Wang, Qi
Zou, Jianzhong
author_sort Wang, Yaotai
collection PubMed
description PURPOSE: The high-intensity focused ultrasound (HIFU) ablation of tumors is inseparable from synergistic agents and image monitoring, but the existing synergistic agents have the defects of poor targeting and a single imaging mode, which limits the therapeutic effects of HIFU. The construction of a multifunctional biological targeting synergistic agent with high biosafety, multimodal imaging and targeting therapeutic performance has great significance for combating cancer. METHODS: Multifunctional biological targeting synergistic agent consisting of Bifidobacterium longum (B. longum), ICG and PFH coloaded cationic lipid nanoparticles (CL-ICG-PFH-NPs) were constructed for targeting multimode imaging, synergistic effects with HIFU and imaging-guided ablation of tumors, which was evaluated both in vitro and in vivo. RESULTS: Both in vitro and in vivo systematical studies validated that the biological targeting synergistic agent can simultaneously achieve tumor-biotargeted multimodal imaging, HIFU synergism and multimodal image monitoring in HIFU therapy. Importantly, the electrostatic adsorption method and the targeting of B. longum to tumor tissues allow the CL-ICG-PFH-NPs to be retained in the tumor tissue, achieve the targeting ability of synergistic agent. Multimodal imaging chose the best treatment time according to the distribution of nanoparticles in the body to guide the efficient and effective treatment of HIFU. CL-ICG-PFH-NPs could serve as a phase change agent and form microbubbles that can facilitate HIFU ablation by mechanical effects, acoustic streaming and shear stress. This lays a foundation for the imaging and treatment of tumors. CONCLUSION: In this work, a biological targeting synergistic agent was successfully constructed with good stability and physicochemical properties. This biological targeting synergistic agent can not only provide information for early diagnosis of tumors but also realize multimodal imaging monitoring during HIFU ablation simultaneously with HIFU treatment, which improves the shortcomings of HIFU treatment and has broad application prospects.
format Online
Article
Text
id pubmed-7085950
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70859502020-04-01 Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent Wang, Yaotai Chen, Chun Luo, Yong Xiong, Jie Tang, Yu Yang, Haiyan Wang, Lu Jiang, Fujie Gao, Xuan Xu, Die Li, Huanan Wang, Qi Zou, Jianzhong Int J Nanomedicine Original Research PURPOSE: The high-intensity focused ultrasound (HIFU) ablation of tumors is inseparable from synergistic agents and image monitoring, but the existing synergistic agents have the defects of poor targeting and a single imaging mode, which limits the therapeutic effects of HIFU. The construction of a multifunctional biological targeting synergistic agent with high biosafety, multimodal imaging and targeting therapeutic performance has great significance for combating cancer. METHODS: Multifunctional biological targeting synergistic agent consisting of Bifidobacterium longum (B. longum), ICG and PFH coloaded cationic lipid nanoparticles (CL-ICG-PFH-NPs) were constructed for targeting multimode imaging, synergistic effects with HIFU and imaging-guided ablation of tumors, which was evaluated both in vitro and in vivo. RESULTS: Both in vitro and in vivo systematical studies validated that the biological targeting synergistic agent can simultaneously achieve tumor-biotargeted multimodal imaging, HIFU synergism and multimodal image monitoring in HIFU therapy. Importantly, the electrostatic adsorption method and the targeting of B. longum to tumor tissues allow the CL-ICG-PFH-NPs to be retained in the tumor tissue, achieve the targeting ability of synergistic agent. Multimodal imaging chose the best treatment time according to the distribution of nanoparticles in the body to guide the efficient and effective treatment of HIFU. CL-ICG-PFH-NPs could serve as a phase change agent and form microbubbles that can facilitate HIFU ablation by mechanical effects, acoustic streaming and shear stress. This lays a foundation for the imaging and treatment of tumors. CONCLUSION: In this work, a biological targeting synergistic agent was successfully constructed with good stability and physicochemical properties. This biological targeting synergistic agent can not only provide information for early diagnosis of tumors but also realize multimodal imaging monitoring during HIFU ablation simultaneously with HIFU treatment, which improves the shortcomings of HIFU treatment and has broad application prospects. Dove 2020-03-17 /pmc/articles/PMC7085950/ /pubmed/32256065 http://dx.doi.org/10.2147/IJN.S238398 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Yaotai
Chen, Chun
Luo, Yong
Xiong, Jie
Tang, Yu
Yang, Haiyan
Wang, Lu
Jiang, Fujie
Gao, Xuan
Xu, Die
Li, Huanan
Wang, Qi
Zou, Jianzhong
Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent
title Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent
title_full Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent
title_fullStr Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent
title_full_unstemmed Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent
title_short Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent
title_sort experimental study of tumor therapy mediated by multimodal imaging based on a biological targeting synergistic agent
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085950/
https://www.ncbi.nlm.nih.gov/pubmed/32256065
http://dx.doi.org/10.2147/IJN.S238398
work_keys_str_mv AT wangyaotai experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT chenchun experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT luoyong experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT xiongjie experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT tangyu experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT yanghaiyan experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT wanglu experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT jiangfujie experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT gaoxuan experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT xudie experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT lihuanan experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT wangqi experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent
AT zoujianzhong experimentalstudyoftumortherapymediatedbymultimodalimagingbasedonabiologicaltargetingsynergisticagent